NASDAQ · Biotechnology

Pluri Inc. (PLUR) Stock

$1.68 -5.62% NASDAQ: PLUR Healthcare

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders.

Valuation

MetricValue
Price$1.68
Market Cap$15.11M
P/E Ratio-0.62
P/B Ratio-0.96
P/S Ratio14.83
EPS (TTM)$-3.56
52-Week High$5.68
52-Week Low$1.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE203.55%
ROA-100.41%
ROCE437.50%
Gross Margin-2300.00%
Operating Margin-2200.00%
Net Margin-24.25%
Debt/Equity-1.81
Current Ratio0.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-51.0M$-42.0M$-27.0M$-22.0M$-22.0M
Net Profit$-50.0M$-41.0M$-28.0M$-21.0M$-23.0M
EPS$-14.19$-10.24$-6.18$-3.99$-3.56
Op Margin—-17774.8%-9493.4%-6796.9%-1659.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$94.0M$68.0M$51.0M$40.0M$39.0M
Total Liabilities$36.0M$36.0M$35.0M$34.0M$40.0M
Cash$31.0M$10.0M$5.0M$7.0M$6.0M
Borrowings$25.0M$29.0M$30.0M$30.0M$34.0M

Latest News

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% GlobeNewswire · Jul 14, 2026 Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing GlobeNewswire · Jun 2, 2026 Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In Insider Monkey · May 30, 2026 Pluri Insider Ups Holding During Year Simply Wall St. · May 28, 2026 Pluri: Fiscal Q3 Earnings Snapshot Associated Press · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-31.0M$-37.0M$-23.0M$-18.0M$-18.0M
Investing Cash Flow$-8.0M$12.0M$9.0M$10.0M$6.0M
Financing Cash Flow$0$10.0M$0$9.0M$0
Net Cash Flow$23.0M$-20.0M$-5.0M$1.0M$0
Free Cash Flow$-31.0M$-37.0M$-23.0M$-18.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-1.72
FCF Yield-132.40%
Quick Ratio0.69
Interest Coverage-22.00
Return 1Y-65.07%
Return 3Y-70.83%
Return 5Y-93.86%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANTX $4.93 +0.20% -4.76 $177.56M 0.00%
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
IBIO $1.45 +1.40% -0.91 $22.89M 0.00%
INTS $4.57 +2.70% -0.60 $12.35M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%

About Pluri Inc.

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

Pluri Inc. is led by CEO Yaacov Yanay, employs 106 people, headquartered in IL, publicly traded since 2003.

Pluri Inc. (PLUR) stock trades at $1.68 with a market capitalization of $15.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.62, price-to-book of -0.96, price-to-sales of 14.83. Over the past 52 weeks the stock has ranged between $1.56 and $5.68, and currently trades 70.4% below its 52-week high.

On profitability, Pluri Inc. generates a return on equity (ROE) of 203.55% — well above the market average, a sign of a high-quality business, return on capital employed of 437.50%, an operating margin of -2200.00%, a net profit margin of -24.25%.

Official website: pluri-biotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides